Tirzepatide-class dual incretin agonist modulating glucose homeostasis and appetite signalling via GIP and GLP-1 pathways.
The research index
Every APEX compound is grounded in published research. Below is a summary of mechanisms and observed benefits per product line — for deeper references open a product page.
Extended-titration tirzepatide analog for sustained receptor engagement in longitudinal studies.
High-concentration incretin agonist for advanced research protocols requiring prolonged half-life.
Truncated growth hormone fragment stimulating lipolysis without affecting IGF-1 or glucose metabolism.
Semaglutide-class GLP-1 analog with albumin binding for extended weekly-dose kinetics.
High-concentration dual GIP/GLP-1 receptor agonist for large-cohort metabolic study lines.
Body Protection Compound 157 modulating VEGF, growth factor pathways, and gastrointestinal repair signalling.
Mitochondrial-derived peptide regulating AMPK signalling, insulin sensitivity and metabolic homeostasis.
Combined Thymosin Beta-4 fragment and BPC-157 for parallel angiogenic and cytoprotective research pathways.
Thymosin Beta-4 fragment supporting actin sequestration, angiogenesis and cell migration in injury models.
Selective PPAR-delta agonist activating fatty acid oxidation and endurance-linked gene expression.
Reduced glutathione peptide complex supporting redox balance and phase II detoxification research.
Copper-binding tripeptide modulating extracellular matrix remodelling, collagen synthesis and skin regeneration.
Nicotinamide adenine dinucleotide precursor supporting sirtuin activation and mitochondrial biogenesis.